Answer in brief: ICH E6(R3) Annex 2 makes modern trial design a systems challenge as much as a protocol challenge. For decentralized, pragmatic and real-world-data trials, sponsors need proportionate oversight, traceable data flows, clear accountability and technology that remains fit for purpose across every location, provider and source.
The guideline does not prescribe a particular platform or operating model. It does, however, raise the practical standard for how trial teams define responsibility, demonstrate control and preserve reliable data when activities, technologies and sources extend beyond a traditional site-based study.
Why ICH E6(R3) Annex 2 matters now
On 10 July 2026, ICH formally adopted Annex Two, completing the E6(R3) revision. The annex focuses on trials that incorporate decentralized elements, pragmatic elements and real-world data. It should be read with the E6(R3) Principles and Annex 1, not as a standalone rulebook.
Teams can review the consolidated E6(R3) guideline to see the common thread: evolving designs and technologies remain acceptable when controls are proportionate to risk and protect participants and trial-result reliability.
The EMA’s Annex Two implementation timeline lists 15 January 2027 as the EU legal effective date. Industry training is already moving toward implementation: DIA’s Annex Two implementation course likewise centers oversight, safety-data collection, digital health technologies and real-world-data fitness for purpose.
What must modern clinical trial systems support?
1. Responsibility that follows the work
A decentralized activity may occur at home, through telehealth, at a local provider or through a digital health technology. Systems should make the responsible investigator, delegated party, source, review status and escalation path visible.
The FDA guidance for decentralized trials reinforces that regulatory requirements do not disappear when an activity moves away from a traditional site.
2. Critical-to-quality controls before configuration
More data does not automatically mean better evidence. Teams should identify the data and processes critical to participant protection and decision-making before configuring forms, edit checks, monitoring plans and dashboards.
That sequence keeps risk controls tied to the protocol instead of adding blanket verification after the study is underway.
3. Traceability across every data handoff
Pragmatic and real-world-data trials may combine electronic health records, registries, claims, devices and trial-specific collection. A defensible data flow shows origin, transformation, transfer, correction and review.
The final FDA electronic systems records guidance explains when electronic systems, records and signatures can be considered trustworthy, reliable and generally equivalent to paper processes.
4. Evidence that real-world data fits its purpose
Real-world data should not enter a trial merely because it is available. Teams need documented access rights, relevant populations and variables, adequate timing, known limitations and a transparent path from source to analysis.
System metadata and version history become part of the evidence that the selected data is suitable for the intended question.
5. Escalation and continuity across providers
Distributed trials introduce more handoffs and service providers. Technology should support safety escalation, issue ownership, access review, contingency processes and retained documentation when a vendor, device or data feed changes.
The goal is not to centralize every task; it is to keep accountability continuous across the trial lifecycle.
How should connected eClinical technology respond?
Connected does not have to mean one monolithic system. It means stable interfaces, shared identifiers, purposeful handoffs and enough context for each role to understand what happened before and what must happen next.
Clinical operations, data management, monitoring and document workflows should reinforce the same critical-to-quality model.
Teams can explore Anju’s connected eClinical suite across trial build, electronic data capture, management and oversight.
For operational visibility, review CTMS Master trial oversight capabilities such as integrated monitoring workflows, protocol-deviation management and connections with EDC and eTMF systems.
Anju also publishes practical risk-based clinical monitoring workflow guidance for focusing resources on the data and processes that matter most.
No software makes a trial compliant by itself. The useful test is whether the configured environment helps trained people apply the protocol, preserve reliable records, see risk signals and demonstrate decisions without reconstructing the story later.
Questions sponsors and CROs should ask now
- Where do participant-facing activities occur, and who retains oversight at each point?
- Which data and processes are critical to quality, and where are their controls configured?
- Can every source, transformation, correction and approval be traced across systems?
- What happens when a provider, device, interface or data source becomes unavailable?
Frequently asked questions
What is ICH E6(R3) Annex 2?
It is the second annex to the revised Good Clinical Practice guideline. It adds considerations for trials using decentralized elements, pragmatic elements and real-world data, while relying on the overarching Principles and Annex 1.
Does Annex 2 require decentralized trials?
No. The guideline does not endorse a particular methodology. It explains how GCP considerations can be applied when these approaches are used, subject to applicable local requirements.
What does Annex 2 mean for trial technology?
Technology should be fit for purpose and support proportionate controls, reliable data, documented access, clear roles, traceable changes and effective oversight across distributed activities and sources.
Where should teams begin?
Start with the protocol’s critical-to-quality factors and a mapped data flow. Then assess roles, vendors, interfaces, monitoring, safety escalation, access controls and contingency plans against that model.
Why life sciences teams trust Anju
Anju develops purpose-built eClinical software for trial design, data capture, management and oversight. Its current eClinical portfolio page documents experience across more than 6,000 clinical trials, 60 countries and 65,000 investigator sites. That domain focus helps teams connect modern trial methods with practical, reviewable operations.
Prepare your trial systems for modern study designs
See how connected eClinical technology can support reliable data, proportionate oversight and traceable workflows across increasingly distributed clinical trials.